{"id":"W2163898107","doi":"10.1016/j.oraloncology.2014.12.013","title":"A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer","year":2015,"lang":"en","type":"article","venue":"Oral Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":78,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital Fleurimont","funders":"National Institute of Dental and Craniofacial Research; National Cancer Institute; Wellcome Trust","keywords":"Medicine; Docetaxel; Internal medicine; Neutropenia; Clinical endpoint; Oncology; Tolerability; Mucositis; Phases of clinical research; Febrile neutropenia; Head and neck cancer; Progression-free survival; Adverse effect; Cancer; Gastroenterology; Randomized controlled trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006026846,0.0003501995,0.00112066,0.0001099846,0.00004810938,0.00002149195,0.0002044996,0.0002290823,0.0000570963],"category_scores_gemma":[0.0001701859,0.0002209329,0.00006581917,0.0002651874,0.0003941021,0.00003459185,0.00007786887,0.0002037685,0.000001781707],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001457127,"about_ca_system_score_gemma":0.001663009,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001156559,"about_ca_topic_score_gemma":0.004766584,"domain_scores_codex":[0.9976139,0.0005228792,0.0005550751,0.0005853048,0.0003045871,0.000418258],"domain_scores_gemma":[0.9985278,0.0000908511,0.0004610908,0.0003551859,0.0002920555,0.0002730036],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9784537,0.002756705,0.01237027,0.00007184668,0.0001300144,0.00006912224,0.0003663494,0.0002344808,0.002596306,0.00000393972,0.000828126,0.002119134],"study_design_scores_gemma":[0.9181993,0.04884754,0.00009562705,0.00006454619,0.0003744361,0.00001319026,0.0001616624,0.0002719803,0.02755008,0.00001419939,0.0040085,0.000398953],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9968004,0.0005583196,0.0001415216,0.00007348762,0.0003488526,0.001856159,0.00006456205,0.00001453674,0.000142136],"genre_scores_gemma":[0.9921194,0.00004797749,0.006554742,0.0002422022,0.000122563,0.0002855729,0.0001164442,0.00005207587,0.0004590686],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06025444,"threshold_uncertainty_score":0.9009382,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03533366139137531,"score_gpt":0.3436311828887238,"score_spread":0.3082975214973485,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}